Cite
HARVARD Citation
Lee, J. et al. (2018). Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet oncology. 19 (2), pp. 207-215. [Online].